Qijun Li

Sir Run Run Shaw Hospital
Hangzhou, 310020, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors.

Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors.

Journal: Journal of hepatocellular carcinoma

Published: May 11, 2026

Exosomes and their roles in the chemoresistance of pancreatic cancer.

Exosomes and their roles in the chemoresistance of pancreatic cancer.

Journal: Cancer medicine

Published: March 07, 2022

Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as "Lung Squamous Cell Carcinoma": A Case Report and Review of the Literature.

Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as "Lung Squamous Cell Carcinoma": A Case Report and Review of the Literature.

Journal: Frontiers in immunology

Published: December 08, 2021

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma.

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma.

Journal: Acta pharmaceutica Sinica. B

Published: October 24, 2021

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.

Journal: Medicine

Published: April 13, 2021

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma.

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma.

Journal: Frontiers in immunology

Published: November 28, 2020

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?

Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?

Journal: Therapeutic advances in medical oncology

Published: September 22, 2019

Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.

Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.

Journal: Medical oncology (Northwood, London, England)

Published: August 16, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026